CARE1: A first-line, randomized platform study to optimize treatment in patients with metastatic renal cell carcinoma.
Phase: Phase II-III clinical trials
Principal Investigator: Dott. Procopio Giuseppe
Main Facility: Oncologia Medica Genitourinaria
Drug: all drugs in clinical practice group A (dual immunotherapy NIVO + IPI Q4W) group B (immunotherapy + anti-angiogenic)
Pathologies: Urological cancers (kidney, bladder, urinary tract, others)
An international, multicenter, open-label, randomized, controlled Phase 3 study comparing the ICI-ICI combination with nivolumab-ipilimumab versus the VEGFR-TKI-ICI combination (axitinib-pembrolizumab, nivolumab-cabozantinib, or lenvatinib-pembrolizumab, at the investigator's discretion based on the available agent). Patients will be stratified by PDL1 status, defined by PDL1 immunohistochemistry (considered positive when >1% of tumor cells are identified by the local pathologist).
Last update: 20/04/2026